Table 2.
Prevalence of markers for infectious diseases among participants in the Young Women's Survey
| No. screened* | Crude prevalence | Weighted prevalence | |||
|---|---|---|---|---|---|
| Disease, disease marker | No. | (%) | 95% CI | % | 95% CI |
| HIV | 2,543 | 7 (0.3) | 0.1-0.6 | 0.3 | 0.1-0.4 |
| Syphilis | 2,424 | 16 (0.7) | 0.4-1.1 | 0.7 | 0.3-1.1 |
| Gonorrhea | 1,336 | 10 (0.8) | 0.4-1.4 | 0.8 | 0.3-1.3 |
| Chlamydia | 1,370 | 42 (3.1) | 2.2-4.2 | 3.3 | 2.4-4.8 |
| Hepatitis A antibody | 1,247 | 425 (34.1) | 31.4-36.7 | 33.5 | 28.3-38.7 |
| Hepatitis B core antibody | 1,337 | 117 (8.8) | 7.3-10.4 | 8.7 | 7.1-10.4 |
| Hepatitis B surface antigen | 1,337 | 9 (0.7) | 0.4-1.1 | 0.8 | 0.3-1.2 |
| Hepatitis C antibody | 1,709 | 40 (2.3) | 1.7-3.2 | 2.5 | 1.4-3.6 |
| Herpes simplex type 1 | 1,663 | 1,256 (75.5) | 73.4-77.6 | 73.7 | 71.6-76.9 |
| Herpes simplex type 2 | 1,663 | 544 (32.7) | 30.5-35.0 | 34.4 | 29.9-39.0 |
| HIV = human immunodeficiency virus; CI = confidence interval. | |||||
*
Specimens were screened for HIV and syphilis in all 5 counties; 4 counties screened for hepatitis C and herpes simplex virus types 1 and 2; and 3 counties screened for gonorrhea, chlamydia, hepatitis A, and hepatitis B. The total number screened does not always equal the total number of women enrolled because of refusal to provide specimens or insufficient quantity of specimen remaining.